The new sensor collects sweat, measures its molecular constituents, such as chloride ions and glucose and then transmits the results for analysis and diagnostics.
Unlike old-fashioned sweat collectors, the new device does not require patients to sit still for a long time while sweat accumulates in the collectors.
The two-part system of flexible sensors and microprocessors sticks to the skin, stimulates the sweat glands and then detects the presence of different molecules and ions based on their electrical signals.
The team at Stanford University in the US used the wearable sweat sensor in separate studies to detect chloride ion levels - high levels are an indicator of cystic fibrosis - and to compare levels of glucose in sweat to that in blood. High blood glucose levels can indicate diabetes.
Conventional methods for diagnosing cystic fibrosis - a genetic disease that causes mucus to build up in the lungs, pancreas and other organs - require that patients visit a specialised centre and sit still while electrodes stimulate sweat glands in their skin to provide sweat for the test.
By comparison, the wearable sweat sensor stimulates the skin to produce minute amounts of sweat, quickly evaluates the contents and beams the data by way of a cellphone to a server that can analyse the results.
People living in remote villages in developing countries, where conventional testing is unavailable, could also benefit from a portable, self-contained sweat sensor, he said.
The wearable device is robust and can be run with a smartphone, which can send measurements to a cloud and receive a result right back after review at a specialised centre.
However, the technology can also be used to measure other molecular constituents of sweat, such as sodium and potassium ions and lactate. The platform can be used to measure virtually anything found in sweat.
"Sweat is hugely amenable to wearable applications and a rich source of information," said Ronald Davis, professor at Stanford.
A wearable sweat sensor allows for frequent monitoring to see how patients respond to a treatment or if they are complying with treatment, said Carlos Milla, associate professor at Stanford.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
